Research

Explore the Year’s Most Innovative Digital Art Projects, Research via Virtual SIGGRAPH 2020 Exhibit

Friday, August 7, 2020 - 10:46pm

SIGGRAPH 2020, the worlds leading computer graphics and interactive techniques conference, will present a special art program of the latest innovations in digital art online this summer.

Key Points: 
  • SIGGRAPH 2020, the worlds leading computer graphics and interactive techniques conference, will present a special art program of the latest innovations in digital art online this summer.
  • Selections include 13 virtual installations as part of the Art Gallery and 15 research advancements within the Art Papers program, including two award-winning juried projects.
  • The virtual exhibit and related sessions will run 1728 August, with content available on-demand through 27 October.
  • SIGGRAPH 2020 , the 47th annual conference hosted by ACM SIGGRAPH, will take place virtually.

Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

Friday, August 7, 2020 - 9:05pm

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Canaccord Genuity 40th Annual Growth Conference on August 13, 2020 at 3:00pm ET.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Canaccord Genuity 40th Annual Growth Conference on August 13, 2020 at 3:00pm ET.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • The companys lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
  • Follow Mirum on Twitter , Facebook and LinkedIn .

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Friday, August 7, 2020 - 9:15pm

Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters option to purchase additional shares, at a price to the public of $30.00 per share.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters option to purchase additional shares, at a price to the public of $30.00 per share.
  • The net proceeds to Veracyte from the offering were approximately $194 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • Goldman Sachs & Co., LLC and SVB Leerink LLC acted as joint lead book-running managers for the offering.
  • The public offering was made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on May 2, 2019.

Laboratory Information Systems Market 2020-2030: COVID-19 Impact - ResearchAndMarkets.com

Friday, August 7, 2020 - 4:52pm

A cloud-based laboratory information system is expected to become the leading trend in the laboratory information systems market.

Key Points: 
  • A cloud-based laboratory information system is expected to become the leading trend in the laboratory information systems market.
  • Thus, a cloud-based laboratory information system is expected to gain significant traction in the laboratory information system market.
  • High costs associated with implementing and maintenance of laboratory information systems are anticipated to limit the growth of the laboratory information system market.
  • It compares the laboratory information system market with other segments of the laboratory information system market by size and growth, historic and forecast.

Florence Welcomes Cooper Anderson as New CFO

Friday, August 7, 2020 - 3:28pm

Florence Healthcare , the leading platform for electronic document workflow management in clinical trials, announces Cooper Anderson as chief financial officer.

Key Points: 
  • Florence Healthcare , the leading platform for electronic document workflow management in clinical trials, announces Cooper Anderson as chief financial officer.
  • Experienced in leading high growth SaaS businesses, Florence brought on Anderson to support a surge in growth as remote site access, monitoring, and collaboration becomes a requirement in clinical trials today.
  • In his new role, Anderson will focus on building and improving the finance function to foster business performance and growth.
  • Before joining Florence, he was a CFO at Acuity, where he worked with high growth technology companies building operational finance teams and facilitated capital raises in both debt and equity.

CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application

Friday, August 7, 2020 - 1:30pm

The median PFS was 7.8 months vs. 4.9 months in CS1001 combined with chemotherapy and placebo combined with chemotherapy, respectively.

Key Points: 
  • The median PFS was 7.8 months vs. 4.9 months in CS1001 combined with chemotherapy and placebo combined with chemotherapy, respectively.
  • We congratulate CStone on this remarkable achievement and contribution to improving potential treatment options for lung cancer.
  • Dr. Frank Jiang, Chairman and CEO of CStone, said, Currently, there is no anti-PD-L1 monoclonal antibody approved for NSCLC in China.
  • CS1001 is the first anti-PD-L1 monoclonal antibody combined with chemotherapy to demonstrate significant improvement in PFS in Chinese NSCLC patients.

Todd Younkin Appointed President and CEO of Semiconductor Research Corporation (SRC)

Friday, August 7, 2020 - 1:18pm

Semiconductor Research Corporation (SRC), a leading global semiconductor research consortium, today announced the appointment of industry veteran Todd Younkin as President and Chief Executive Officer.

Key Points: 
  • Semiconductor Research Corporation (SRC), a leading global semiconductor research consortium, today announced the appointment of industry veteran Todd Younkin as President and Chief Executive Officer.
  • That research initiative emphasizes the advancement of Computer Science, Electrical Engineering, and Materials Science to secure continued U.S. thought leadership in the global semiconductor industry.
  • SRC is a major driving force behind the university research that spurs innovation in the semiconductor industry and throughout our economy, said John Neuffer, President and CEO of the Semiconductor Industry Association (SIA).
  • Through its interdisciplinary research programs, SRC plays an indispensable part to address global challenges, using research and development strategies, advanced tools and technologies.

Illumina to Webcast Upcoming Investor Conference Presentation

Friday, August 7, 2020 - 1:55pm

Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

Key Points: 
  • Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
  • The live webcasts can be accessed in the Investor Info section of Illumina's web site under the "company" tab at www.illumina.com .
  • A replay of the presentations will be posted on Illuminas website after the event and will be available for at least 30 days following.
  • Illumina is improving human health by unlocking the power of the genome.

Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update

Friday, August 7, 2020 - 12:15pm

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.
  • Despite the challenges caused by the global pandemic, it has been a very productive quarter for Ocular Therapeutix, said Antony Mattessich, President and CEO.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 8:30 am Eastern Time to review the Company's financial results and provide a general business update.
  • Ocular Therapeutix recently completed a Phase 3 clinical trial evaluating DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis.

Utrecht University and Bruker Announce Collaboration to Develop Methods for Studying Protein Structures and Interactions by Mass Spectrometry

Friday, August 7, 2020 - 12:00pm

Bruker Corporation (Nasdaq: BRKR) today announced a collaboration with Utrecht University to advance the study of the 3-D structures and interactions of proteins by mass spectrometry.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced a collaboration with Utrecht University to advance the study of the 3-D structures and interactions of proteins by mass spectrometry.
  • The laboratory of Albert Heck at Utrecht University has been a leader in proteomics and the study of protein structure and interactions by mass spectrometry for over two decades.
  • Richard Scheltema recently joined Utrecht University as group leader to focus on crosslinking mass spectrometry (XL-MS) for structural and interaction proteomics.
  • Complementary to the proteomics efforts, the group is also well-known for its expertise in mass spectrometry based structural biology, pioneering methods in native mass spectrometry and cross-linking mass spectrometry.